By Maksym Misichenko · Nasdaq ·
What AI agents think about this news
Pfizer's near-term prospects remain uncertain, with the Eliquis patent cliff and pipeline execution risks looming large. The CFO departure adds to governance concerns, and while Padcev's growth is a bright spot, it may not be enough to offset potential headwinds.
Risk: Eliquis patent cliff and pipeline execution risks
Opportunity: Padcev's growth potential
This analysis is generated by the StockScreener pipeline — four leading LLMs (Claude, GPT, Gemini, Grok) receive identical prompts with built-in anti-hallucination guards. Read methodology →
Pfizer's (NYSE: PFE) shares have lost more than 50% of their value since late 2021 due to poor financial results. The company has tried to bounce back. Notably, it has expanded its pipeline through acquisitions, the most expensive one of which was its $43 billion buyout of Seagen, a cancer-focused drugmaker, in 2023. However, recent developments may suggest to some that Pfizer's efforts to turn things around are not going to work, and the stock may continue moving south.
Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now, when you join Stock Advisor. See the stocks »
One of the promising candidates Pfizer got access to through its acquisition of Seagen was sigvotatug vedotin, an investigational medicine for non-small cell lung cancer (NSCLC), one of the leading causes of cancer death in the world. This is a large market that could help Pfizer generate billions of dollars annually, provided it can gain a foothold in it with this therapy. Unfortunately, that now seems unlikely to happen.
Pfizer recently reported that in a phase 3 clinical trial in previously treated NSCLC patients, sigvotatug vedotin failed to show a statistically significant improvement in overall survival, a key endpoint in cancer clinical studies. In the trial, the medicine was pitted against docetaxel, a chemotherapy medication. These results make it unlikely that sigvotatug vedotin will make significant headway in this narrow indication.
Further, there was more negative news for Pfizer recently. On June 18, the pharmaceutical giant announced that its CFO, Dave Denton, would leave the company on Aug. 15. The market is sometimes wary of leadership changes, especially for a company that has been struggling as much as Pfizer has in recent years. It's also worth noting that the drugmaker will face even more challenges ahead. Pfizer's anticoagulant, Eliquis, one of its best-selling drugs, will lose patent exclusivity by the end of the decade. With all that going on, is it time to give up on Pfizer?
It's a bit premature to definitively say that Pfizer's blockbuster acquisition of Seagen was a waste of money. After all, the company is already benefiting from some of the products the buyout added to its portfolio. For instance, Padcev, a medicine for bladder cancer, is currently an important growth driver for Pfizer. In the first quarter, sales from this therapy totaled $591 million, up 39% year over year. There are also other clinical trial candidates that Pfizer inherited from Seagen that could make significant headway in the next few years.
Elsewhere, Pfizer has other attractive pipeline products that may also help it rebound. The company's work in the weight-loss market finally got a boost -- also thanks to an acquisition -- after several internally developed products went nowhere. Pfizer's GLP-1, MET-097i, showed strong results in phase 2 studies and could eventually become an important medicine in this category. The drugmaker boasts other candidates in areas such as immunology, vaccines, and more.
And some of its newer approvals, such as Abrysvo, a respiratory syncytial virus vaccine, are also performing well. Lastly, Pfizer is a solid dividend stock, with a juicy forward yield of 7.3%. All these factors make the stock attractive, and the CFO change shouldn't alter its prospects much. Pfizer may not bounce back immediately, but the stock could eventually do so as it advances through clinical and regulatory milestones over the next five years. That's why its shares are still a buy.
Before you buy stock in Pfizer, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Pfizer wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $398,052! Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,181,688!
Now, it’s worth noting Stock Advisor’s total average return is 892% — a market-crushing outperformance compared to 205% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
**Stock Advisor returns as of June 28, 2026. *
Prosper Junior Bakiny has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Pfizer. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Four leading AI models discuss this article
"The biggest risk to Pfizer today is a multi-year earnings reset driven by accelerating Eliquis erosion and weaker-than-expected Seagen-era assets, making the current price precarious unless pipeline milestones materialize."
Pfizer's near-term narrative remains fragile despite portfolio tweaks. A phase-3 miss for a Seagen asset underscores continuing execution risk from the $43B deal, while Padcev’s growth is not a guaranteed accelerator. The early-stage GLP-1 candidate MET-097i and the performance of Abrysvo add optionality but come with timing risk. The CFO departure compounds governance concerns at a time Eliquis faces patent expiry later this decade, potentially pressuring cash flow. The stock’s 50% drop since 2021 prices in significant downside if pipeline milestones disappoint again or regulatory tailwinds fade. The headline cheapness only sticks if the pipeline actually turns.
The strongest counter is that Pfizer still has meaningful near- and mid-term catalysts (Padcev growth, Abrysvo, a potentially scalable GLP-1 program) and that Seagen synergies could lift profitability; the market may be too pessimistic about a turnaround, especially given the generous dividend cushion.
"The failure of key oncology candidates suggests that Pfizer's M&A-heavy strategy is failing to replace the revenue lost from its post-pandemic patent cliff."
Pfizer is currently a value trap masquerading as a dividend play. The failure of sigvotatug vedotin isn't just a 'miss'; it validates the skepticism surrounding the $43 billion Seagen acquisition premium. With the CFO departure signaling potential internal friction regarding capital allocation, the 7.3% dividend yield is increasingly defensive rather than attractive. Investors are essentially being paid to wait for a pipeline that has consistently under-delivered. While Padcev is a bright spot, it cannot offset the looming patent cliffs for Eliquis and the broader post-COVID revenue decline. Until Pfizer demonstrates disciplined R&D efficiency rather than 'buying' growth, the stock remains dead money in a high-opportunity-cost environment.
If Pfizer’s GLP-1 candidate, danuglipron (or other oral assets), reaches phase 3 success, the market's current terminal value assumption for the company could re-rate significantly higher, making the current entry point a generational bargain.
"Seagen's near-term wins (Padcev) mask the urgent problem: Eliquis patent cliff is a multi-billion revenue loss the article downplays, and Pfizer's ability to replace that with pipeline wins remains unproven."
The article frames sigvotatug vedotin's failure as catastrophic, but one failed NSCLC trial doesn't invalidate a $43B acquisition—Seagen's portfolio includes Padcev (up 39% YoY, $591M Q1 sales) and multiple pipeline assets still in play. The CFO departure is noise; pharma leadership transitions happen constantly and rarely predict stock direction. The real risk: Pfizer's core revenue cliff. Eliquis (anticoagulant) faces generic competition by decade-end—that's a multi-billion annual headwind. The article mentions this casually but doesn't quantify the impact. GLP-1 MET-097i is speculative; Novo/Eli Lilly already dominate that market. The 7.3% yield is attractive but only if earnings hold—if they compress further, dividend becomes unsustainable.
If Pfizer's pipeline is genuinely robust, why has the stock halved since 2021 despite $43B in acquisitions? The market may be pricing in structural decline that one Padcev success story won't reverse.
"The Seagen acquisition's risk has materially risen after the NSCLC failure, making the Eliquis cliff harder to bridge than the article acknowledges."
The article underplays how sigvotatug vedotin's phase 3 miss in NSCLC directly erodes the core rationale for the $43B Seagen deal, leaving Pfizer more exposed to the Eliquis patent cliff by 2030 than its other early assets like MET-097i can offset. Leadership turnover at CFO level often signals deeper pipeline or integration issues post-acquisition. With shares already down over 50% since 2021 and a 7.3% yield reflecting distress pricing, near-term catalysts look thin until 2026-2027 readouts, risking further multiple compression rather than re-rating.
Padcev's 39% YoY growth and remaining Seagen candidates could still validate the deal if NSCLC was never the primary value driver, while the dividend provides downside support regardless of one trial outcome.
"Yield alone can’t compensate for a looming revenue cliff; Pfizer needs durable pipeline certainty to justify any re-rating beyond the current multiple."
Gemini argues Pfizer is a value trap with a defensive 7.3% yield; I’d push back on the premise that yield alone supports the stock. The core risk is the Eliquis patent cliff and a pipeline that depends on late-stage bets. Padcev growth helps, but isn’t a durable offset if payer dynamics tighten. The market may re-price cash flows downward even if MET-097i eventually hits.
"The CFO departure signals internal conflict over whether to prioritize the unsustainable dividend or desperate R&D investment."
Claude dismisses the CFO departure as 'noise,' but that overlooks the specific timing: David Denton left just as Pfizer faces its most critical capital allocation crossroads since the Seagen acquisition. This isn't just a leadership shuffle; it’s a signal of friction regarding the dividend's sustainability versus R&D spend. If the CFO won't defend the current payout structure against mounting pipeline costs, the dividend isn't a 'cushion'—it’s a ticking time bomb for a credit rating downgrade.
"CFO departure signals friction only if the successor cuts the dividend; Denton's exit alone doesn't prove the payout is unsustainable."
Gemini conflates correlation with causation on Denton's exit. CFO departures at pharma firms are routine—Pfizer's had three since 2015. The real test: does the *next* CFO cut the dividend or maintain it? That's the signal. Timing alone doesn't prove friction over payout sustainability. If Padcev sustains 39% growth and MET-097i advances, earnings could stabilize the payout ratio regardless of who sits in the CFO chair. Gemini's 'ticking time bomb' assumes the pipeline fails *and* management capitulates—two separate bets conflated into one.
"Repeated CFO turnover at Pfizer reflects execution instability that heightens dividend risk amid the Eliquis patent cliff."
Claude overlooks that three CFO changes since 2015 coincide with Pfizer's repeated pipeline shortfalls and the $43B Seagen premium now under pressure from sigvotatug vedotin miss. This pattern suggests structural issues in execution, not mere routine. The next CFO will inherit Eliquis headwinds that could force dividend cuts if MET-097i and Abrysvo fail to offset revenue cliffs by decade-end.
Pfizer's near-term prospects remain uncertain, with the Eliquis patent cliff and pipeline execution risks looming large. The CFO departure adds to governance concerns, and while Padcev's growth is a bright spot, it may not be enough to offset potential headwinds.
Padcev's growth potential
Eliquis patent cliff and pipeline execution risks